Should You Buy Novo Nordisk Stock on Oral Wegovy's Strong Launch?

Novo Nordisk received December approval for an oral version of Wegovy and launched it earlier this month, with initial prescription volume reportedly higher in the first two weeks than the original injectable Wegovy and Eli Lilly’s Zepbound at equivalent launch stages. Despite lower per-patient pricing that will likely limit near-term revenue versus injectables, some forecasts project peak annual sales for oral Wegovy of roughly $3.3 billion; the company also has a deep pipeline including CagriSema (outperformed Wegovy in phase 3) and late-stage Amycretin. Competition is expected to intensify as Eli Lilly plans its own oral GLP-1 later this year, but strong early demand plus multiple upcoming product candidates supports a constructive outlook for Novo Nordisk’s revenue growth even as the stock remains well below its levels from two years ago.

Analysis

Market structure: Oral Wegovy expands addressable market by converting needle-averse and uninsured patients into users, favoring NVO (near-term winner) and retail pharmacies/CMOs that can scale oral production. Injectable incumbents (Eli Lilly’s Zepbound/LLY) face mix shift pressure—expect downward pressure on average revenue per patient even if patient volumes rise; models should assume oral ASP ~40–60% of injectable given commentary on lower out-of-pocket cost. Cross-asset: positive credit/FX for Danish cashflows modest; expect equity IV for NVO/LLY to reprice higher near product news and bond spreads to tighten slightly if guidance improves.

Risk assessment: Tail risks include payor restrictions (step therapy or formulary exclusions), safety label action from adverse-event clusters, and faster-than-expected price competition if multiple orals launch—each could shave 30–60% off published peak sales scenarios. Time horizons: days—prescription data and sentiment moves; weeks–months—payor negotiations and Lilly oral launch; years—CagriSema/Amycretin trial outcomes drive material upside or downside. Hidden dependencies: reimbursement rules (Medicare/insurers) and manufacturing scale for oral tablets are key second-order constraints.

Trade implications: Establish a defined-risk long on NVO sized 1.5–3% of portfolio via equity or debit call spread to capture 12-month upside (~+25–40%) while limiting downside (stop-loss -15%). Run a pair trade: long NVO / short LLY (1:1 notional) sized 1% to play relative share reversion ahead of Lilly’s oral launch; hedge with cash or index exposure. Use options: buy 6–9 month NVO call spread (25%/45% OTM) sized 0.5–1% and buy a 30–60 day LLY straddle around its oral launch window to hedge competitive shock.

Contrarian angles: Consensus underweights expansion value — oral could increase total GLP-1 users by >20% over 2–3 years even if ASPs fall, meaning sell-side peak sales may be conservative. Conversely, market may be underpricing regulatory/payor risk; if insurers limit coverage, downside could be abrupt. Historical parallel: PCSK9 adoption showed initial enthusiasm but rapid pricing pressure from competitive entrants—prepare for similar ASP erosion scenarios.

Key Decisions for Investors

• Establish a 1.5–3% long position in Novo Nordisk (NVO) within 2 weeks via equity or a 6–9 month call debit spread (buy 25% OTM, sell 45% OTM) targeting a 12-month +25–40% return; set a hard stop-loss at -15%.
• Initiate a relative-value pair: long NVO / short Eli Lilly (LLY) sized 1% each (dollar-neutral) for a 6–12 month horizon to capture potential NVO share recovery; trim if Lilly’s oral launch is delayed or NVO weekly Rx growth falls below 2% week-over-week for two consecutive weeks.
• Buy a 30–60 day LLY straddle (centered on its oral GLP-1 launch date) sized 0.5–1% to hedge event volatility and monetize potential large moves; exit within 7 days post-launch.
• Reduce exposure by ~20–30% to small-cap obesity/GLP-1 pure-plays lacking phase-3 assets today; redeploy proceeds into NVO and defensive healthcare names if NVO week-over-week Rx growth sustains >10% for four consecutive weeks.
• Monitor three specific catalysts over the next 30–90 days before scaling: (1) weekly oral Wegovy prescription growth (threshold >10% WoW sustained = scale long), (2) payor formulary updates/Medicare guidance (restrictive = reduce exposure), (3) Lilly oral launch date and initial uptake (strong uptake = revisit pair sizing).